MTOR and breast cancer: Of note, both the stroma-intensive expression of Zscan4 in the post-treatment patients and significant correlations between Zscan4 and p38/mTOR were validated through pathological assessment of human breast cancer (BCa) patient samples (Supplementary Fig. 2a–i).